Trials / Unknown
UnknownNCT05235542
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
A Phase Ib/II Study of AK104#PD-1 / CTLA-4 Bispecific Antibody# and AK117#Anti-CD47 Antibody# in Combination With or Without Chemotherapy in Advanced Malignant Tumors
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) and AK117#AntiCD47 Antibody# combined with or without chemotherapy in advanced malignant tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK104 | IV infusion,Specified dose on specified days |
| DRUG | AK117 | IV infusion,Specified dose on specified days |
| DRUG | Capecitabine tablets | Oral,Specified dose on specified days |
| DRUG | Oxaliplatin | IV infusion,Specified dose on specified days |
| DRUG | Cisplatin | IV infusion,Specified dose on specified days |
| DRUG | Paclitaxel | IV infusion,Specified dose on specified days |
| DRUG | Irinotecan | IV infusion,Specified dose on specified days |
| DRUG | Docetaxel | IV infusion,Specified dose on specified days |
| DRUG | 5-FU | IV infusion,Specified dose on specified days |
Timeline
- Start date
- 2022-07-12
- Primary completion
- 2023-03-01
- Completion
- 2024-03-01
- First posted
- 2022-02-11
- Last updated
- 2022-08-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05235542. Inclusion in this directory is not an endorsement.